FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W4212830947> ?p ?o ?g. }

• W4212830947 endingPage "320" @default.
• W4212830947 startingPage "320" @default.
• W4212830947 abstract "320 Background: Immune checkpoint combination therapy (ICI-combo) is the new standard of care for mRCC in first-line setting. However, pts with poor PS (≥2) were excluded from pivotal trials. Hence, the activity and safety of ICI-combo in this group of pts is still unknown. Methods: We performed a multicentre retrospective study of PS≥2 mRCC pts who received ICI-combo, either nivolumab-ipilimumab (NI) or pembrolizumab-axitinib (PA) as first-line treatment between 2017-2021. Patient’s characteristics, clinical outcomes and toxicity were retrospectively reviewed. We analysed overall response rate (ORR), disease control rate (DCR), progression-free survival (PFS), overall survival (OS) and grade ≥3 treatment-related adverse events (G≥3 AEs) in pts treated with NI or PA. The association between LIPI (Lung Immune Prognostic Index) and ORR, PFS and OS was also evaluated. Results: We identified 56 mRCC pts with PS≥2 treated with ICI-combo across 13 institutions. Thirty-six and 20 pts were treated with NI and PA respectively. Median age at diagnosis was 64 (31-83) years, 38 (68%) were male, 16 (29%) had prior nephrectomy and 40 (71%) had synchronous metastatic disease at diagnosis. Respectively, 19 (34%) and 37 (66%) pts were intermediate and poor risk according to IMDC. Fifty pts (89%) were clear cell RCC, and only 4 pts had sarcomatoid features reported. At the time of analysis (median follow-up 11.1 months(mo)) 45% pts were dead. The ORR for the entire cohort was 27%; ORR was numerically higher with PA (42%) than with NI (20%) but did not reach statistical significancy (p=0.157). Median PFS (mPFS) and mOS in the entire cohort were 4.4 mo and 15.9 mo respectively. No significant differences in PFS, OS or the rate of G≥3AEs were seen between the NI and PA groups. Efficacy and toxicity outcomes are described in the table below. No significant differences in OS or PFS according to the IMDC risk score were observed (p=0.818). However, LIPI was significantly associated with OS (poor LIPI: HR=8.18; p=0.004) and PFS (Intermediate LIPI: HR=2.4; p=0.048 and poor LIPI: HR=8.59; p<0.001). LIPI was predictive of response in patients treated with NI (p=0.024). Conclusions: We report the first cohort of PS≥2 mRCC pts treated with ICI-combo in first-line setting. No significant differences in ORR, PFS or OS were seen between NI and PA. LIPI was significantly associated with both OS and PFS, and was predictive of ORR in the NI group. Prospective real-world studies are needed to confirm these results.[Table: see text]" @default.
• W4212830947 created "2022-02-24" @default.
• W4212830947 creator A5003970424 @default.
• W4212830947 creator A5004554295 @default.
• W4212830947 creator A5016485718 @default.
• W4212830947 creator A5017845725 @default.
• W4212830947 creator A5019500272 @default.
• W4212830947 creator A5030771495 @default.
• W4212830947 creator A5030902321 @default.
• W4212830947 creator A5032392359 @default.
• W4212830947 creator A5035257097 @default.
• W4212830947 creator A5042535284 @default.
• W4212830947 creator A5049672639 @default.
• W4212830947 creator A5054850662 @default.
• W4212830947 creator A5058652974 @default.
• W4212830947 creator A5060923356 @default.
• W4212830947 creator A5061239712 @default.
• W4212830947 creator A5064217794 @default.
• W4212830947 creator A5074162105 @default.
• W4212830947 creator A5079847176 @default.
• W4212830947 creator A5081355165 @default.
• W4212830947 creator A5088690292 @default.
• W4212830947 date "2022-02-20" @default.
• W4212830947 modified "2023-10-18" @default.
• W4212830947 title "Efficacy of first-line combination therapy in metastatic renal cell carcinoma (mRCC) patients (pts) with poor performance status (PS)." @default.
• W4212830947 doi "https://doi.org/10.1200/jco.2022.40.6_suppl.320" @default.
• W4212830947 hasPublicationYear "2022" @default.
• W4212830947 type Work @default.
• W4212830947 citedByCount "1" @default.
• W4212830947 countsByYear W42128309472022 @default.
• W4212830947 crossrefType "journal-article" @default.
• W4212830947 hasAuthorship W4212830947A5003970424 @default.
• W4212830947 hasAuthorship W4212830947A5004554295 @default.
• W4212830947 hasAuthorship W4212830947A5016485718 @default.
• W4212830947 hasAuthorship W4212830947A5017845725 @default.
• W4212830947 hasAuthorship W4212830947A5019500272 @default.
• W4212830947 hasAuthorship W4212830947A5030771495 @default.
• W4212830947 hasAuthorship W4212830947A5030902321 @default.
• W4212830947 hasAuthorship W4212830947A5032392359 @default.
• W4212830947 hasAuthorship W4212830947A5035257097 @default.
• W4212830947 hasAuthorship W4212830947A5042535284 @default.
• W4212830947 hasAuthorship W4212830947A5049672639 @default.
• W4212830947 hasAuthorship W4212830947A5054850662 @default.
• W4212830947 hasAuthorship W4212830947A5058652974 @default.
• W4212830947 hasAuthorship W4212830947A5060923356 @default.
• W4212830947 hasAuthorship W4212830947A5061239712 @default.
• W4212830947 hasAuthorship W4212830947A5064217794 @default.
• W4212830947 hasAuthorship W4212830947A5074162105 @default.
• W4212830947 hasAuthorship W4212830947A5079847176 @default.
• W4212830947 hasAuthorship W4212830947A5081355165 @default.
• W4212830947 hasAuthorship W4212830947A5088690292 @default.
• W4212830947 hasConcept C121608353 @default.
• W4212830947 hasConcept C126322002 @default.
• W4212830947 hasConcept C141071460 @default.
• W4212830947 hasConcept C143998085 @default.
• W4212830947 hasConcept C197934379 @default.
• W4212830947 hasConcept C2776539811 @default.
• W4212830947 hasConcept C2777472916 @default.
• W4212830947 hasConcept C2777701055 @default.
• W4212830947 hasConcept C2779490328 @default.
• W4212830947 hasConcept C2780030458 @default.
• W4212830947 hasConcept C2780057760 @default.
• W4212830947 hasConcept C2780739268 @default.
• W4212830947 hasConcept C2781433595 @default.
• W4212830947 hasConcept C3019894029 @default.
• W4212830947 hasConcept C71924100 @default.
• W4212830947 hasConcept C90924648 @default.
• W4212830947 hasConceptScore W4212830947C121608353 @default.
• W4212830947 hasConceptScore W4212830947C126322002 @default.
• W4212830947 hasConceptScore W4212830947C141071460 @default.
• W4212830947 hasConceptScore W4212830947C143998085 @default.
• W4212830947 hasConceptScore W4212830947C197934379 @default.
• W4212830947 hasConceptScore W4212830947C2776539811 @default.
• W4212830947 hasConceptScore W4212830947C2777472916 @default.
• W4212830947 hasConceptScore W4212830947C2777701055 @default.
• W4212830947 hasConceptScore W4212830947C2779490328 @default.
• W4212830947 hasConceptScore W4212830947C2780030458 @default.
• W4212830947 hasConceptScore W4212830947C2780057760 @default.
• W4212830947 hasConceptScore W4212830947C2780739268 @default.
• W4212830947 hasConceptScore W4212830947C2781433595 @default.
• W4212830947 hasConceptScore W4212830947C3019894029 @default.
• W4212830947 hasConceptScore W4212830947C71924100 @default.
• W4212830947 hasConceptScore W4212830947C90924648 @default.
• W4212830947 hasIssue "6_suppl" @default.
• W4212830947 hasLocation W42128309471 @default.
• W4212830947 hasOpenAccess W4212830947 @default.
• W4212830947 hasPrimaryLocation W42128309471 @default.
• W4212830947 hasRelatedWork W2947020554 @default.
• W4212830947 hasRelatedWork W3027525046 @default.
• W4212830947 hasRelatedWork W3086501416 @default.
• W4212830947 hasRelatedWork W3092591340 @default.
• W4212830947 hasRelatedWork W3211505627 @default.
• W4212830947 hasRelatedWork W4214621369 @default.
• W4212830947 hasRelatedWork W4221029189 @default.
• W4212830947 hasRelatedWork W4226442571 @default.
• W4212830947 hasRelatedWork W4285189908 @default.
• W4212830947 hasRelatedWork W4310754081 @default.
• W4212830947 hasVolume "40" @default.

• next